Vaxcyte (PCVX) Projected to Announce Earnings on Tuesday

Key Points

• Vaxcyte is expected to report Q3 2026 results after Tuesday’s market close. Analysts forecast a loss of $2.11 per share and revenue of $12.50 million; the earnings call is scheduled for November 4 at 4:00 p.m. ET.
• The company’s previous quarter exceeded expectations, with an adjusted loss of $1.97 per share versus the $2.06 consensus estimate. Analysts project full-year and next-year losses of $7.47 and $6.36 per share, respectively.
• Wall Street maintains a generally positive outlook: seven analysts rate the stock Buy, one rates it Hold, and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $110.50 versus a recent share price near $59.97.

Vaxcyte (NASDAQ:PCVX - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($2.11) per share and revenue of $12.50 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the company earned ($1.22) EPS. On average, analysts expect Vaxcyte to post ($7.47) EPS for the current fiscal year and ($6.36) EPS for the next fiscal year.

Vaxcyte Stock Down 0.8%

Shares of PCVX stock opened at $59.97 on Tuesday. Vaxcyte has a one year low of $39.87 and a one year high of $90.75. The stock has a 50-day moving average of $61.53 and a 200-day moving average of $56.54.

Insider Buying and Selling at Vaxcyte

In other news, CAO Elvia Cowan sold 19,000 shares of Vaxcyte stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $86.74, for a total value of $1,648,060.00. Following the completion of the sale, the chief accounting officer directly owned 27,860 shares in the company, valued at approximately $2,416,576.40. The trade was a 40.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet Dhaliwal sold 17,000 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the sale, the insider owned 76,756 shares of the company's stock, valued at approximately $4,221,580. This trade represents a 18.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,692 shares of company stock valued at $5,308,175 over the last ninety days. Company insiders own 3.30% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $120.00 price target on shares of Vaxcyte in a research report on Monday, October 12th. Wall Street Zen raised Vaxcyte from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Bank of America cut their price objective on Vaxcyte from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday, September 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a research report on Friday, October 2nd. Finally, Needham & Company LLC raised their target price on shares of Vaxcyte from $110.00 to $122.00 and gave the stock a "buy" rating in a research note on Monday, October 5th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $110.50.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte's lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.